Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 665-678 , October 2009

Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment

  • Lucy R. Wedderburn, MD, PhD (Reader and Consultant in Paediatric Rheumatology)

      Affiliations

    • Rheumatology Unit, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 207 905 2391; fax: +44 207 813 8494.
    • ,
  • Lisa G. Rider, MD (Deputy Unit Chief, Environmental Autoimmunity Group)

      Affiliations

    • Environmental Autoimmunity Group, Office of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA

References 

  1. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 2008;58:3585–3592
  2. Christen-Zaech S, Seshadri R, Sundberg J, et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;58:571–576
  3. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34:732–736
  4. Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49:300–305
  5. McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)–clinical characteristics of children recruited within the first 5 yr. Rheumatology. 2006;45:1255–1260
  6. Wedderburn LR, Li CK. Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol. 2004;18:345–358
  7. Pachman LM, Lipton R, Ramsey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53:166–172
  8. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201–2212
  9. Bohan A, Peter JB. Polymyositis and dermatomyositis (two parts). N Engl J Med. 1975;292:344–347403–7
  10. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology. 2004;43:603–608
  11. Brown VE, Pilkington CA, Feldman BM, Davidson JE. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology. 2006;45:990–993
  12. Wedderburn LR, Varsani H, Li CK, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum. 2007;57:1192–1201
  13. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52:2607–2615
  14. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol. 2009;27:363–391
  15. Constantin T, Ponyi A, Orban I, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary–clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006;39:223–232
  16. Mamyrova G, O'Hanlon TP, Sillers L, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 2008;58:3941–3950
  17. Pachman LM, Jonasson O, Cannon RA, Friedman JM. Increased frequency of HLA-B8 in juvenile dermatomyositis. Lancet. 1977;2:1238
  18. Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol. 1991;32:235–240
  19. Mamyrova G, O'Hanlon TP, Monroe JB, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006;54:3979–3987
  20. Wedderburn LR, McHugh NJ, Chinoy H, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis–scleroderma overlap. Rheumatology. 2007;46:1786–1791
  21. Chinoy H, Payne D, Poulton K, et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PMScl antibody positive idiopathic inflammatory myopathy. Rheumatology, in press, doi:10.1093/rheumatology/kep248.
  22. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43:2368–2377
  23. Chinoy H, Platt H, Lamb JA, et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum. 2008;58:3247–3254
  24. O'Hanlon TP, Rider LG, Schiffenbauer A, et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum. 2008;58:3239–3246
  25. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–3199
  26. Chinoy H, Salway F, John S, et al. Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology. 2007;46:1411–1416
  27. Manlhiot C, Liang L, Tran D, et al. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford). 2008;47:526–529
  28. Pachman LM, Litt DL, Rowley AH, et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthritis Rheum. 1995;38:1513–1518
  29. Mamyrova G, Rider LG, Haagenson L, et al. Parvovirus B19 and onset of juvenile dermatomyositis. JAMA. 2005;294:2170–2171
  30. Vegosen LJ, Weinberg CR, O'Hanlon TP, et al. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum. 2007;56:2719–2728
  31. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 1997;23:619–655
  32. Gunawardena H, Betteridge Z, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48:607–612
  33. Feldman BM, Reichlin M, Laxer RM, et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol. 1996;23:1794–1797
  34. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006;85:111–127
  35. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689
  36. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology. 2008;47:324–328
  37. Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87:70–86
  38. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60:1807–1814
  39. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201:591–601
  40. Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196:781–791
  41. Eloranta ML, Barbasso Helmers S, Ulfgren AK, et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56:3112–3124
  42. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002;168:4154–4163
  43. O'Connor KA, Abbott KA, Sabin B, et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol. 2006;120:319–325
  44. Miles L, Bove KE, Lovell D, et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum. 2007;57:1183–1191
  45. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990;27:343–356
  46. Lundberg I, Ulfgren AK, Nyberg P, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:865–874
  47. Sallum AM, Marie SK, Wakamatsu A, et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol. 2004;31:801–807
  48. Fall N, Bove KE, Stringer K, et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum. 2005;52:3175–3180
  49. Nagaraju K, Rider LG, Fan C, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis. 2006;3:2
  50. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13:59–68
  51. Lopez de Padilla CM, Vallejo AN, McNallan KT, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007;56:1658–1668
  52. Lopez De Padilla CM, Vallejo AN, Lacomis D, et al. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum. 2009;60:1160–1172
  53. Reed AM, McNallan K, Wettstein P, et al. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?. J Immunol. 2004;172:5041–5046
  54. Li CK, Varsani H, Holton JL, et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004;31:605–609
  55. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA. 2000;97:9209–9214
  56. Salomonsson S, Grundtman C, Zhang SJ, et al. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve. 2009;39:674–682
  57. Li C, Knopp P, Moncrieffe H, et al. Over expression of MHC class l heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol, in press, doi:10.2353/ajpath.2009.090196.
  58. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology. 2001;40:1262–1273
  59. Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology. 2003;42:1452–1459
  60. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59:4–13
  61. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50:2281–2290
  62. Ruperto N, Woo P, Cuttica R, et al. The validated PRINTO core set and definition of improvement for juvenile myositis. Arthritis Rheum. 2004;50(S):S534
  63. Ravelli A, Ruperto N, Trail L, et al. Clinical assessment in juvenile dermatomyositis. Autoimmunity. 2006;39:197–203
  64. Huber AM, Dugan EM, Lachenbruch PA, et al. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology. 2007;46:1606–1611
  65. Huber AM, Dugan EM, Lachenbruch PA, et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. 2008;59:214–221
  66. Huber AM, Lachenbruch PA, Dugan EM, et al. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum. 2008;59:352–356
  67. Dugan EM, Huber AM, Miller FW, Rider LG. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J. 2009;15:1
  68. Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49:7–15
  69. Smith RL, Sundberg J, Shamiyah E, et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004;31:1644–1649
  70. Rouster-Stevens KA, Gursahaney A, Ngai KL, et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59:222–226
  71. Carroll CL, Lang W, Snively B, et al. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol. 2008;158:345–350
  72. Klein RQ, Bangert CA, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol. 2008;159:887–894
  73. Apaz MT, Saad-Magalhaes C, Pistorio A, et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum. 2009;61:509–517
  74. Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis using the myositis damage index. Arthritis Rheum, in press.
  75. Traill L, Ruperto N, Pilkington CA, et al. The long-term outcome of juvenile idiopathic inflammatory myopathies: a multicenter, multinational study of 557 patients. Arthritis Rheum. 2007;52:S830
  76. Sanner H, Gran JT, Sjaastad I, Flato B. Organ damage and prognostic factors in juvenile dermatomyositis. Ann Rheum Dis. 2009;68(Suppl):S500
  77. McCann LJ, Garay SM, Ryan MM, et al. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology. 2007;46:1363–1366
  78. Coyle K, Rother KI, Weise M, et al. Metabolic abnormalities and cardiovascular risk factors in children with myositis. J Paediatrics, in press, doi:10.2353/ajpath.2009.090196.
  79. Kimball AB, Summers RM, Turner M, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum. 2000;43:1866–1873
  80. Rider LG. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:935–977
  81. Bilgic H, Ytterberg SR, McNallan KT, et al. IL-17 and IFN-regulated genes and chemokines as biomarkers of disease activity in inflammatory myopathies. Arthritis Rheum. 2008;58:S922
  82. Zipitis CS, Baildam EM, Ramanan AV. Treatment approaches to juvenile dermatomyositis. Expert Opin Pharmacother. 2004;5:1509–1515
  83. Maillard SM, Jones R, Owens CM, et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum. 2005;53:558–564
  84. Pilkington CA, Wedderburn LR. Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs. 2005;65:1355–1365
  85. Kim S, El-Hallak M, Dedeoglu F, et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60:1825–1830
  86. Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52:3570–3578
  87. Seshadri R, Feldman BM, Ilowite N, et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59:989–995
  88. Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology. 2004;43:491–496
  89. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology. 2005;44:386–389
  90. Rouster-Stevens KA, Pachman L. Mycophenolate mofetil in juvenile dermatomyositis. Arthritis Rheum. 2006;54:S680
  91. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762–1763
  92. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27:1469–1471
  93. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601–607
  94. Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56:3107–3111
  95. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763–767
  96. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy–rare but there!. Leuk Lymphoma. 2009;50:1083–1095
  97. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology. 2008;47:877–880
  98. Miller ML, Smith R, Abbott KA, et al. Use of Etanercept in chronic juvenile dermatomyositis. Arthritis Rheum. 2002;44(Supplement):S306
  99. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–1677
  100. Holzer U, van Royen-Kerkhof, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scandinavian Journal of Rheumatology, in press, doi:10.1080/03009740903096622
  101. Rider LG. The heterogeneity of juvenile myositis. Autoimmun Rev. 2007;6:241–247

☆ Acknowledgements of grant funding: This work was supported in part by grants from the Wellcome Trust UK, Action Medical Research UK, the UK Myositis Support Group and the intramural research program of the National Institute of Environmental Health Sciences, National Institutes of Health, USA.

PII: S1521-6942(09)00080-1

doi: 10.1016/j.berh.2009.07.007

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 665-678 , October 2009

Article Tools